SSS Sunvest Minerals Corp

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS), a biopharmaceutical company
developing cancer stem cell-related technologies, today announced that its
wholly owned subsidiary Trillium Therapeutics has completed dosing in its Phase
I study of TTI-1612 in patients with interstitial cystitis/bladder pain syndrome
(IC/BPS). The study was designed to assess the safety and tolerability of single
ascending doses of TTI-1612 in IC/BPS patients. Pharmacokinetics and changes in
disease symptoms were also evaluated. A total of 28 patients were enrolled at
four urology clinics in Southern Ontario. Preliminary data indicate that the
drug is well tolerated and exhibits a favourable pharmacokinetic profile. Full
results are expected to be published at a later date.


IC/BPS, also known as Painful Bladder Syndrome, is a chronic, debilitating and
poorly treated bladder disease affecting millions of people. The disease is
believed to develop as a result of dysfunction in the protective epithelial
layer lining the bladder. TTI-1612, a locally-delivered recombinant growth
factor, is being developed to correct the dysfunction and restore the bladder
epithelium to a normal, healthy state.


This urology program, acquired by Stem Cell Therapeutics through its recent
merger with Trillium Therapeutics, targets an indication of high unmet need and
represents a substantial market opportunity. However, with its current focus on
oncology and cancer stem cells, the Company will now actively seek a development
partner to conduct the next phase of the clinical development program.


"Completing dosing in this clinical study in a timely manner is a significant
early milestone in the development of TTI-1612," commented Dr. Bob Uger, the
Company's Chief Scientific Officer. "We are encouraged by our clinical
experience to date with this drug, and believe we are setting the groundwork for
a partner to move this program forward into Phase II testing."


About Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS):

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic bladder
disease characterized by increased urinary urgency and/or frequency, nocturia
(waking from sleep to urinate) and pelvic pain. These symptoms are often severe,
and can impact both the physical and emotional health of patients. For many
IC/BPS sufferers the disease adversely affects all major aspects of their lives,
including social relationships, travel, leisure activities and employment. Once
considered a rare disease, IC/BPS is now recognized as an increasingly common
medical problem. Recently, a large epidemiological study found that 3.3 to 7.9
million women and 2 million men in the US alone suffer from IC symptoms. Current
therapies often provide inadequate relief, and many IC/BPS patients report
dissatisfaction with available treatment options. Since the current pipeline of
new IC/BPS drugs is largely focused on analgesics and is unlikely to
significantly alter the IC treatment landscape, novel and innovative approaches
to treatment are needed.


About Stem Cell Therapeutics:

Stem Cell Therapeutics Corp. (SCT), a Toronto-based biopharmaceutical company,
is Canada's only public company dedicated to advancing cancer stem cell
discoveries into novel and innovative cancer therapies. Building on over half a
century of leading and groundbreaking Canadian stem cell research, the company
is supported by established links to multiple Toronto academic institutes and
oncology treatment centers that represent one of the world's most acclaimed
cancer research hubs. SCT's lead clinical program, which targets a metabolic
pathway in leukemia blasts and leukemic stem cells, is currently being evaluated
in a multi-centre Phase I study in patients with relapsed or refractory Acute
Myeloid Leukemia (AML). The Company also has two premier preclinical programs,
SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key
immunoregulatory pathways that tumor cells exploit to evade the host immune
system. SIRPaFc is an antibody-like fusion protein that blocks the activity of
CD47, a molecule that is upregulated on cancer stem cells in AML and several
other tumors. The CD200 mAb is a fully human monoclonal antibody that blocks the
activity of CD200, an immunosuppressive molecule that is overexpressed by many
hematopoietic and solid tumors. For more information, visit:
www.stemcellthera.com


Caution Regarding Forward-Looking Information:

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include changing market conditions; the successful and timely completion
of pre-clinical and clinical studies; the establishment of corporate alliances;
the impact of competitive products and pricing; new product development risks;
uncertainties related to the regulatory approval process or the ability to
obtain drug product in sufficient quantity or at standards acceptable to health
regulatory authorities to complete clinical trials or to meet commercial demand;
and other risks detailed from time to time in SCT's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, SCT undertakes no
obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
Dr. Niclas Stiernholm
Chief Executive Officer
+1 416 595 0627
niclas@stemcellthera.com
www.stemcellthera.com

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024